Ticker

Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,493 shares of the specialty pharmaceutical company's stock, valued at approximately $1,611,000. Freestone Grove Partners LP owned

BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,441,202 shares of the specialty pharmaceutical company's stock, valued at approximately $196,972,000. BlackRock Inc. owned about 16.78% of Collegium

On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.39. Over the past year, the stock has seen significant volati

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will…

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Profitability This table compares Collegium Pharmaceutical…